BBIO: BridgeBio Pharma, Inc.
About
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Current Value
$22.421 Year Return
Current Value
$22.421 Year Return
Key Details
Market Cap
$4.26B
P/E Ratio
-9.34
1Y Stock Return
-20.38%
1Y Revenue Growth
2209.77%
Dividend Yield
0.00%
Price to Book
-3.5
Strategies that include BBIO
Stock's related to BBIO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BPMC | 46.45% | $6.01B | +42.68% | 0.00% |
| CVCO | 42.18% | $3.82B | +69.11% | 0.00% |
| ARR | 41.67% | $1.05B | +8.10% | 16.27% |
| SFBS | 41.46% | $5.11B | +85.58% | 1.29% |
| ORC | 40.64% | $615.55M | +6.95% | 18.46% |
| PATK | 40.37% | $2.90B | +54.53% | 1.67% |
| WD | 40.20% | $3.61B | +30.99% | 2.42% |
| CLFD | 40.11% | $398.66M | +4.48% | 0.00% |
| PLYM | 39.90% | $842.88M | -11.32% | 5.12% |
| ALKS | 39.61% | $4.45B | +15.66% | 0.00% |
| ALDX | 39.56% | $294.18M | +102.46% | 0.00% |
| NMRK | 39.55% | $2.60B | +94.74% | 0.79% |
| HOUS | 39.41% | $459.51M | -15.54% | 0.00% |
| HASI | 39.39% | $3.29B | +16.65% | 5.90% |
| RYTM | 39.31% | $3.69B | +79.50% | 0.00% |
| ATEX | 39.29% | $617.94M | +5.94% | 0.00% |
| ACLX | 39.27% | $4.74B | +69.19% | 0.00% |
| BY | 39.24% | $1.36B | +51.33% | 1.18% |
| AMWD | 39.23% | $1.46B | +29.41% | 0.00% |
| BRSP | 39.22% | $806.64M | -3.86% | 12.20% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRK | 0.05% | $4.10B | +33.84% | 0.88% |
| BNED | 0.06% | $277.22M | -91.94% | 0.00% |
| CNQ | 0.08% | $71.04B | +1.89% | 6.81% |
| AADI | -0.15% | $54.47M | -52.78% | 0.00% |
| CYCN | -0.15% | $4.77M | -16.19% | 0.00% |
| HESM | -0.16% | $3.78B | +14.54% | 7.24% |
| TAL | -0.16% | $4.54B | +2.16% | 0.00% |
| SM | -0.19% | $5.02B | +16.26% | 1.68% |
| MVO | -0.25% | $106.15M | -22.78% | 16.78% |
| AVAV | -0.31% | $5.50B | +51.29% | 0.00% |
| CI | -0.31% | $89.70B | +12.57% | 1.68% |
| PRPH | 0.54% | $18.14M | -82.61% | 0.00% |
| DMLP | 0.55% | $1.58B | +18.00% | 10.54% |
| VRN | 0.56% | $3.23B | -25.43% | 6.21% |
| RNR | -0.57% | $13.74B | +23.09% | 0.58% |
| RILY | 0.57% | $145.72M | -79.86% | 20.75% |
| NEUE | -0.60% | $40.93M | -34.13% | 0.00% |
| HLF | 0.62% | $778.11M | -38.09% | 0.00% |
| NFE | -0.62% | $2.29B | -74.75% | 3.32% |
| KSPI | -0.64% | $20.86B | +18.06% | 3.37% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -14.15% | $35.67M | +7.92% | 0.00% |
| LITB | -13.69% | $35.48M | -75.45% | 0.00% |
| UUU | -13.11% | $4.97M | -41.89% | 0.00% |
| CME | -12.18% | $82.76B | +9.21% | 1.98% |
| PRT | -11.37% | $48.72M | -16.56% | 10.33% |
| HUSA | -11.30% | $16.69M | -11.56% | 0.00% |
| MNR | -11.25% | $1.66B | -10.71% | 15.90% |
| ALNY | -10.59% | $30.22B | +43.13% | 0.00% |
| IMO | -9.41% | $39.72B | +31.84% | 2.23% |
| SHEL | -8.86% | $205.19B | -1.07% | 4.20% |
| CTRA | -8.65% | $19.37B | -0.90% | 3.20% |
| PGR | -8.47% | $149.10B | +57.29% | 0.45% |
| BSM | -8.47% | $3.17B | -13.01% | 10.65% |
| NNE | -8.38% | $833.66M | +531.50% | 0.00% |
| COR | -8.29% | $47.48B | +21.20% | 0.86% |
| CYD | -7.37% | $364.46M | -2.94% | 4.26% |
| SU | -7.31% | $52.05B | +23.58% | 3.92% |
| TTE | -7.14% | $138.45B | -11.95% | 5.50% |
| DOGZ | -7.07% | $614.77M | +1,372.26% | 0.00% |
| MCK | -7.01% | $78.15B | +35.51% | 0.42% |
ETF's related to BBIO
News
Yahoo
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene. Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease The OL
Yahoo
One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) - they aren't optimistic, having...
Yahoo
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension- The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidi
Finnhub
MDP858 RELATIONSHIP BETWEEN CVH AND SURVIVAL IN THE ACORAMIDIS-TREATED PARTICIPANTS WITHIN ATTRibute-CM ...
Finnhub
MDP857 EVOLVING BASELINE RISK IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A...
Finnhub
ACORAMIDIS REDUCES ALL-CAUSE MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION : INITIAL OUTCOMES FROM THE ATTRibute-CM OPEN-LABEL EXTENSION STUDY ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.